Navigation Links
Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
Date:11/16/2009

NEW YORK, Nov. 16 /PRNewswire/ -- Personalized Pharmaceutical Systems (PPS) today announced the sale of the Angioedema Clinical Prediction Guide to Viropharma Incorporated.

PPS is a clinical trial enrichment and market differentiation company which has developed advanced technology in phenomics to help drug companies identify the correct patients for their drugs, and as a result help patients get the right drug the first time. Through the use of its phenomic technology, PPS developed the Angioedema Clinical Prediction Guide to help emergency room physicians quickly differentiate amongst different types of angioedema (AE) that can be life-threatening.

Allergic angioedema is more common, and can be treated with antihistaminergic treatments. Hereditary Angioedema (HAE) is a rare form of AE seen in less than 1% of AE patients presenting to emergency rooms, and is not treatable with antihistaminergic treatments. Due to both the rareness of HAE and the complexity of differentiating amongst the various types of AE, the HAE patient is often misdiagnosed and treated inappropriately in the emergency room, increasing the risk of life-threatening airway compromise.

Correct diagnosis of HAE is known to take, on average, several years from a patient's first visit to an emergency room. Viropharma has licensed the Angioedema Clinical Prediction Guide and is currently considering a large-scale retrospective validation analysis. If validated, Viropharma may use the Angioedema Clinical Prediction Guide as a component of their medical education strategy to give physicians a means to recognize rarer forms of AE, and thereby accelerate the referral and diagnosis of HAE.

"We are extremely pleased with this opportunity for Viropharma to use our technology to accelerate the diagnosis of patients with this very severe disease. We look forward to the possibility of future collaboration and new opportunities to optimize Viropharma's clinical trial design, increase physician awareness, and maximize patient access," Dr. Paul Herscu, CEO, PPS.

About Personalized Pharmaceutical Systems LLC

Personalized Pharmaceutical Systems (PPS) is a cutting edge clinical trial enhancement and market differentiation company designed to dramatically reduce risk for pharmaceutical companies in both drug development and post-market entry phases. PPS novel enrichment technology utilizes inter-individual variability, that currently confounds drug trials, to enhance efficacy outcomes and/or significantly reduce risk of adverse effects. PPS technology effectively dissects diagnostic populations into treatment response correlated subgroups through the analysis of thousands of clinical indices measured against a continuum of environmental variables. While most clinical trials currently compare 40-50 clinical indices against clinical outcomes, PPS templates consider over 1000 indices mapped against a continuum of environmental variations and tested in thousands of patients over the past 15 years. This level of granularity brings a new level of precision to provide reliable determination of true clinical phenotype at the whole patient level. This technology creates new opportunity for success with compounds that are stalled or failing in current trials. PPS technology can be seamlessly incorporated into existing Phase II-IV trials.

SOURCE Personalized Pharmaceutical Systems


'/>"/>
SOURCE Personalized Pharmaceutical Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
3. Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients
4. Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
5. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
6. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
7. Personalized Medicine Expert: Dont Fix It, Predict It
8. Personalized Medicine Killer Apps Will Transform Care Model
9. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
10. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
11. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
(Date:5/25/2016)... 25, 2016 ReportsnReports.com adds ... report that provides an overview on therapeutic pipeline ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Chronic ...
Breaking Medicine Technology:
(Date:5/28/2016)... , ... May 28, 2016 , ... SuperCloset is proud ... too well the day to day issues, struggles and obstacles veterans’ need to overcome ... Veterans Grow Project provides active or retired military veteran(s) with a donated SuperCloset product ...
(Date:5/28/2016)... ... May 28, 2016 , ... In a part of the city where’s it’s easy to spot ... Kelowna restaurants is hoping to attract diners with a taste for real food. ... opened the doors to Cornerstone Grill, an urban casual restaurant focusing on dishes made by ...
(Date:5/27/2016)... New Hampshire (PRWEB) , ... May 27, 2016 , ... ... skin care products, announced today that it has been recognized as one of the ... entering parenthood. Badger was named as one of nine small businesses providing progressive benefits ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign aimed at ... stories, courtesy of awareness-driven celebrities and thought leaders. It also provides insight to ... industry leaders such as Bioness. , As patients feel increasingly concerned about ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
Breaking Medicine News(10 mins):